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Abstract
Human ageing has been predicted to be caused by the accumulation of molecular damage in cells and tissues. Somatic
mitochondrial DNA (mtDNA) mutations have been documented in a number of ageing tissues and have been shown to be
associated with cellular mitochondrial dysfunction. It is unknown whether there are selective constraints, which have been
shown to occur in the germline, on the occurrence and expansion of these mtDNA mutations within individual somatic
cells. Here we compared the pattern and spectrum of mutations observed in ageing human colon to those observed in the
general population (germline variants) and those associated with primary mtDNA disease. The pathogenicity of the protein
encoding mutations was predicted using a computational programme, MutPred, and the scores obtained for the three
groups compared. We show that the mutations associated with ageing are randomly distributed throughout the genome,
are more frequently non-synonymous or frameshift mutations than the general population, and are significantly more
pathogenic than population variants. Mutations associated with primary mtDNA disease were significantly more pathogenic
than ageing or population mutations. These data provide little evidence for any selective constraints on the occurrence and
expansion of mtDNA mutations in somatic cells of the human colon during human ageing in contrast to germline mutations
seen in the general population.
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Introduction
Ageing is a stochastic process commonly defined as the
progressive decline in the condition of an organism which is
accompanied by a reduction in fertility and an increasing risk of
death [1]. Ageing is unlikely to be genetically programmed as
evolution theory suggests that nature would not select for a process
which is generally harmful to the viability of the organism [2]. The
disposable soma theory [3,4] suggests that there are ‘trade-offs’
between somatic cell maintenance, growth and reproduction.
Under constant pressure of natural selection to make optimal use
of resources, organisms can afford to make only limited investment
in the maintenance and repair of somatic tissues. Metabolic
processes associated with tissue maintenance are costly and there is
no advantage in keeping somatic cells in good condition beyond
the typical survival period in the wild, plus a little reserve. This
contrasts with the requirement to protect the germline, where
constant high maintenance is needed to maximise capacity for
reproduction in the current generation, and to minimise the risk of
transferring damage. Nowadays most humans survive long past
the life expectancy of our distant ancestors, and experience ageing
due to the gradual accumulation of unrepaired damage in somatic
cells.
Damage to mitochondrial DNA (mtDNA) resulting in dysfunc-
tion of the oxidative phosphorylation (OXPHOS) system has been
proposed to be an important contributor to the ageing phenotype
[5]. The mitochondrial genome is a circular, double-stranded,
,16.5 Kb molecule [6] encoding 13 essential polypeptides of the
OXPHOS system in addition to 24 mt-RNA genes required for
their translation. Its organisation is an example of extreme
economy; the vast majority of the molecule is coding and there
are no introns, so mutation of the mtDNA is likely to have a
functional effect. However, given that there are multiple copies of
mtDNA within individual cells, the vast majority of mutations are
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functionally recessive and a detectable OXPHOS defect occurs
only when a critical threshold level of mutant mtDNA is exceeded
[7]. A commonly used assay to look for cells or tissues with
mtDNA mutations is a histochemical test to demonstrate
cytochrome c oxidase (COX) activity [8]. Cells lacking functional
COX activity commonly contain mtDNA mutations at high levels
[9,10], and whilst this assay may not pick up all mutations it is a
good initial screen.
MtDNA is inherited in a non-Mendelian manner exclusively
through the female line [11] and bi-parental recombination, if it
has ever occurred, has left no footprint on the phylogeny [12].
Asexual inheritance should leave the mitochondrial genome
vulnerable to extinction due to the irreversible accumulation of
mtDNA mutations, a process known as Muller’s Ratchet [13]. In
the absence of recombination, the only means to prevent this
outcome is a selection process against mutants which is strong
enough to substantially abate the relatively high mutation rate
experienced by mtDNA. In principle, selection against mtDNA
mutations can act at several levels since cells typically contain large
numbers of mtDNA molecules which have a replication cycle that
is not strictly coupled with that of the cell itself [14]. Selection
against mtDNA mutations could therefore arise (i) through direct
competition between mtDNA variants within the cell, (ii) through
selection at the cell level, if mutants affect cellular survival and/or
division, or (iii) through selection at the whole organism level, via
effects on fitness of the individual.
A distinctive mechanism that is thought to enhance the power of
selection to keep mtDNA mutations in check within the germline is
the mitochondrial ‘‘bottleneck’’ [15]. The bottleneck event
effectively samples mtDNA molecules ensuring only a small
proportion are selected to form the mtDNA pool [16] in the
mature oocyte which is passed to the offspring. The mammalian
oocyte contains over 100,000 mtDNA molecules which do not
replicate during early embryogenesis [11]. They segregate during
cell division events and when the primordial germ cells are formed
they contain only 200–400 mtDNA molecules [17]. As primordial
germ cells differentiate into mature oocytes which will transmit
their mtDNA to the next generation [18], there is re-initiation of
mtDNA replication of a small subset of mtDNA molecules [19].
Currently it is a matter of intense debate as to whether this
expansion occurs during embryogenesis or post-natal follicular-
genesis [17,19], but regardless of the exact timing, deleterious
mutations will either be lost or they will be more strongly exposed
to natural selection and, if not eliminated, become fixed more
rapidly [20]. Germline selection adds to the purifying selection of
mtDNA that had already been shown to occur in human
populations by comparison of different lineages [21,22]. Together
the population studies and experimental studies in the mouse
[23,24] demonstrate a multi-level selective process which can act
to remove deleterious and slightly deleterious variants.
While the full repertoire of mechanisms to combat mtDNA
mutation accumulation act within the germline, there is less of an
imperative to prevent such accumulation within the soma, and
there are fewer opportunities to do so. Somatic mtDNA mutations
have been shown to accumulate to high levels in a number of
human ageing tissues including brain, heart, skeletal muscle,
colon, stomach and liver, leading to OXPHOS dysfunction
[10,25–29]. Thus, the accumulation of mtDNA mutations in the
soma of ageing humans may contribute to the decline in cellular
functionality commonly seen during ageing. In addition mouse
models with increased levels of mitochondrial DNA (mtDNA)
mutations [30–32] show a premature ageing phenotype suggesting
that mitochondrial defects are important in the ageing process.
Although the accumulation of age-associated somatic mtDNA
mutations is not subject to the full set of selective constraints that
operate in the germline, it is possible that selection at the
intracellular and intercellular levels could influence the spectrum
of mutations that is seen. Experimental support for this hypothesis
is limited and information on the pattern of mtDNA mutations
which occur with age is likely to inform our understanding of the
underlying mechanisms that might be involved. Previous studies
have shown that there are differences in the type of mutations
detected with ageing in post-mitotic and mitotic tissues. In post-
mitotic tissues the predominant mutated species are large-scale
mtDNA deletions [33–36], whereas in dividing cells mtDNA point
mutations are commonly identified [9,26,27,37–39]. As large-scale
mtDNA deletions are rarely transmitted through the germline we
investigated possible selective constraints only on mtDNA point
mutations which occur somatically during human ageing by
analysing location, mutation type and predicted mutation path-
ogenicity using the human colon as a model ageing system. We
have previously generated a number of mtDNA sequences from
ageing colonocytes [9,10,38] providing an excellent data set of
age-related somatic mutations for investigation. We then com-
pared the mutational spectra with germline mtDNA point
mutations seen in a geographically-comparable human population
and well-characterised pathogenic mtDNA point mutations which
are documented causes of primary mtDNA disease phenotypes.
Results
A dataset of age-related mtDNA mutations
In order to ensure that we had a high quality data set of age-
related somatic mtDNA mutations to use in the subsequent
analyses, 72 individual cells from 9 participants over 70 years of
age were sequenced, and the presence of clonally-expanded
mtDNA mutations was documented. These data were combined
with those which we have published previously on human colon
(age range 70–76 years) [9,10,38]. In our previous studies cells
were sequenced based on the absence or presence of COX
activity. The majority of cells were COX deficient as these studies
Author Summary
Mitochondrial DNA encodes essential components of the
mitochondrial respiratory chain and is strictly maternally
inherited, making it vulnerable to the accumulation of
deleterious mutations. To avoid this, mtDNA is subjected
to a bottleneck phenomenon whereby only a small
number of mtDNA molecules are passed on to the oocyte
precursor. These are then amplified to the required
number of mtDNA molecules in the mature oocyte,
meaning that any mutations may be either lost or rapidly
fixed. Purifying selection is thought to be an important
protective mechanism against pathogenic mtDNA muta-
tions in the germline, as this is essential for mtDNA
stability. It is unknown whether there are any such
protective mechanisms in the somatic tissues. To investi-
gate this we have compared the spectrum of mutations
present in ageing human colonocytes with those popula-
tion variants passed through the maternal germline and
mtDNA mutations responsible for primary mtDNA disease.
We show that pathogenic mtDNA mutations are present
at a significantly higher frequency in the somatic cells of
the human colon in contrast to variants that have
passed though the germline, showing little evidence for
purifying selection in the somatic tissues studied here,
but strong evidence of this selective mechanism in the
germline.
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aimed to detect the underlying genetic defect in these cells. This
strategy increases the likelihood of detecting pathogenic mtDNA
mutations. Here we wanted to obtain a more complete picture of
the mutational spectrum across the human colon including non-
pathogenic mutations and those which do not affect COX activity,
therefore we sequenced an additional 48 COX positive cells and
24 COX deficient cells. This gave a total of 156 whole
mitochondrial mtDNA sequences (71 sequences are from COX
positive cells and 85 from COX deficient cells [26,32,33]). These
sequences yielded a collection of 129 clonally-expanded mtDNA
point mutations which were found in 89 different cells. 67 of the
cells in this dataset did not contain any clonally expanded mtDNA
mutations. Heteroplasmy levels were estimated based on the ratio
of peak heights on the electropherograms. A relatively high
proportion of the mutations (39%) were present at homoplasmic
levels, however we believe that this is due to the fact that crypts
were selected based on their COX activity rather than any
selective mechanism. COX deficient cells contained 88% of the
homoplasmic mutations. This highlights the fact that the majority
of mtDNA mutations require a high level of mutation to be
reached before a biochemical defect is observed [7]. Of the cells
which contained mtDNA mutations, the majority (61) contained
only one mutation, 20 contained 2 mutations, 5 contained 3
mutations and 3 contained 4 or more mutations. Where there
were multiple mutations present only 5 cells contained mutations
that were present at the same levels of heteroplasmy and in all
cases this was 100%, the remaining cells had varying levels of
heteroplasmy, indicating that each mutation occurred at different
times or on different molecules. All mutations in the data set are
listed in Table S1 along with their COX status. Only mutations in
the coding region were included in the following analyses, as
mutations in these regions are more likely to have deleterious
effects. From here on the somatic mutations detected in the human
colon will be referred to as ‘somatic’ or ‘age-related’ mutations.
Age-related mtDNA mutations occur randomly within
the genome
To investigate the location of the changes on the mtDNA of
age-associated mutations they were grouped by base pair number
(per 2000 bases; 1–2000, 2001–4000 etc). Based on the assumption
that all groups had an equal chance of containing a mutation, chi-
squared analysis showed no significant difference in the observed
and expected frequencies (p = 0.293) which supports the conclu-
sion that age-associated mutations are located randomly through-
out the mitochondrial genome.
To be confident that these mutations truly were random they
were then grouped according to gene status (e.g. whether they
occurred within mt-tRNA, mt-rRNA or protein encoding genes).
Similarly, the difference between the observed and expected
frequencies was not significant (p = 0.129) (chi-squared analysis
comparing observed to expected frequencies based on the
proportion of the genome occupied by each gene type). A
comparison was then made with the disease (full mutation list in
Table S2) and population variants (full list in Table S3) (Figure 1A).
In the disease-associated mutation group, there was a significantly
higher proportion of mutations in mt-tRNA genes (53%)
compared to other gene types (p,0.0003). This has been reported
previously in other studies [23,40]. In the rare population variants,
the majority of mutations were in the protein encoding genes
(85%) (p,0.003), probably because a high proportion of the
changes in the protein encoding genes of the population predict
synonymous amino acid changes which are non-pathogenic and
are therefore unlikely to be selected against in the germline. The
nature of changes (e.g. transitions, transversions and insertions/
deletions) was then examined in the three groups. In all cases, the
overwhelming majority of changes were transitions (90%, 94%
and 87% in age-related mutations, population variants and disease
mutations respectively). There was a significantly higher frequency
of insertion and deletion mutations in the both the age-related
mutation group compared to the population variants, and the
disease mutation group compared to the population variants
(p,0.003 in both cases, contingency analysis with Bonferroni
correction for multiple testing, Figure 1B).
Non-synonymous mtDNA mutations are present more
frequently during ageing and mtDNA disease than in
populations
Purifying selection models have shown that, in the germline,
selection is strongest against mutations in protein-encoding genes
which cause an amino acid change [23], those which predict a
frameshift, or those which cause premature translation termination
[19]. A comparison of such mutations in the three data sets was made
(Figure 2A). This revealed a significantly higher number of non-
synonymous (65.4%) and frameshift/premature termination codons
(16.5%) in the ageing cells compared with the rare population variant
group (34% and 0.6% respectively) (contingency analysis with
Bonferroni correction for multiple testing, p,0.0003). This suggests
that human somatic cells are not protected from accumulation of age-
related deleterious mutations in the same way as has been shown
during germline transmission of mtDNAmutations in the mouse [23].
Comparison of age-associated mutations and disease-causing muta-
tions revealed a significantly higher number of frameshift/premature
termination codons in the disease group (32%) (p,0.0003).
To investigate further the apparent selection-free environment,
from the stand point of mtDNA mutations, in somatic cells,
protein encoding disease-causing mutations were grouped accord-
ing to whether these had been reported as ‘inherited’ or ‘sporadic’
mtDNA mutations (as defined in the original reports, see Table S2
for details). Whilst inherited mtDNA mutations are passed through
the germline, it is proposed that sporadic mutations occur during
early embryological development beyond the point of the genetic
bottleneck [17,19]. Further examination of frameshift and
termination codon mutations (which might be predicted to be
the most pathogenic) showed that a significantly higher number
were sporadic (78%) rather than inherited (22%) (chi-squared
analysis, p = 0.003) (Figure 2B), supporting the idea that these
arose after the selective check point.
Age-related and disease-causing mutations in protein-
encoding genes are more pathogenic than rare
population variants
Pathogenicity of the non-synonymous mutations in the three
groups was predicted using MutPred software [41], and the groups
compared. The MutPred score is determined by a set of features
reflecting protein structure, evolutionary conservation, presence of
functional residues and amino acid biases at the substitution site and
its neighbours. Amino acid variants are identified by comparison to
their counterparts defined by the rCRS sequence [42]. Mutations are
assigned a score between 0 and 1, with higher pathogenicity scores
corresponding to a greater likelihood that the amino acid change is
pathogenic. Only non-synonymous protein encoding gene mutations
were used in this analysis because the software is unable to analyse the
pathogenicity of frameshift mutations and those which predict a
premature termination codon. In addition, pathogenicity scores for
all possible amino acid changes in the mitochondrial genome,
predicted by the MutPred software (published as a supplementary
table in [43]) were included in these analyses (Figure 3A). There was
Absence of Selection in Somatic mtDNA Mutations
PLOS Genetics | www.plosgenetics.org 3 November 2012 | Volume 8 | Issue 11 | e1003082
no significant difference in the mean pathogenicity score between
the age-related mutations (0.65160.203 (sd), n = 52) and all possible
mutations (0.64260.154, n=24206) (p= 0.94, Wilcoxon rank sum
test). This evidence supports the hypothesis that there are no
selective constraints on mutations which accumulate in the human
colon during ageing. The age-related mtDNA mutations had
significantly higher MutPred scores (0.65160.203, n= 52) than the
rare population mtDNA mutations (0.48160.202, n= 53)
(p,0.00017) but significantly lower scores than disease-associated
mtDNA mutations (0.76160.13, n= 54) (p= 0.0016), supporting
the hypothesis that these mutations occur at random during the life-
course and their expansion is not curtailed by purifying selection.
Figure 1. Gene location and types of mutations observed in ageing, population, and disease. A: Gene location of mutations. Data are
represented as the percentage of the total coding region mutations. Contingency analysis with Bonferroni correction for multiple testing was carried
out on the frequencies of the changes in each gene type (ageing n= 117, population n= 182, disease n = 176). Thresholds for statistical significance
are; ***,0.0003, ** 0.003, * = 0.017. B: Types of changes observed in ageing, population and disease. Data are represented as the percentage of the
total coding region mutations. Contingency analysis with Bonferroni correction for multiple testing was carried out on the frequencies of the changes
in each mutational category. Thresholds for statistical significance are; ***,0.0003, ** 0.003, * = 0.017.
doi:10.1371/journal.pgen.1003082.g001
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To obtain a more complete picture of the pathogenicity of the
protein encoding mtDNA mutations, the synonymous mutations in
the ageing and population groups (there were none in the disease
group) were assigned a pathogenicity score of 0 (as they do not change
an amino acid and are therefore very unlikely to have a functional
effect) and included in the analysis (Figure 3B). There were significant
differences between the three groups (Wilcoxon rank sum tests,
p,0.0003 in all cases) with pathogenicity scores highest in the
disease-associated mutation group (0.76160.13, n=54) followed by
age-associated mutations (0.51360.323, n=66) and population
variants (0.17160.26, n=149). Given the very high pathogenicity
scores predicted in the disease mutation group, mutations in this
group were separated into inherited and sporadic mutations and the
mean scores compared (Figure 3C). Mean MutPred pathogenicity
score was significantly higher in the sporadic mutation group
(0.83160.059, n=16) compared with the inherited mutations
(0.73760.136, n=26) (p= 0.02, Wilcoxon rank sum test).
MtDNA mutations in other somatic tissues
All of the above analyses have been based on somatic mtDNA
point mutations detected in individual ageing human colonic
crypts as this is the most comprehensive dataset of such mutations
to date. However it is known that there are differences in mutation
Figure 2. Genetic consequences of mutations observed in ageing, population, and disease. A: The percentage of changes which predict
synonymous, non-synonymous and premature termination codons or frameshifts in protein encoding genes. Contingency analysis with Bonferroni
correction for multiple testing was carried out on the frequencies of the changes in each gene type (ageing n= 81, population n= 155, disease
n = 76). Thresholds for statistical significance are; ***,0.0003, ** 0.003, * = 0.017. B: Frequency of termination codon and frameshift mutations in
inherited and sporadic disease-causing mtDNA mutations. Chi-squared analysis showed a significantly higher frequency such mutations in sporadic
than inherited cases (p = 0.003).
doi:10.1371/journal.pgen.1003082.g002
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PLOS Genetics | www.plosgenetics.org 5 November 2012 | Volume 8 | Issue 11 | e1003082
Figure 3. MutPred pathogenicity scores of mtDNA mutations in ageing, populations, disease, and all possible mtDNA mutations. A:
The distribution of pathogenicity scores in ageing, populations, disease and all possible mutations. Results of Wilcoxon rank sum analysis are shown.
Absence of Selection in Somatic mtDNA Mutations
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occurrence and accumulation between different tissues. For
example clonally expanded point mutations and not large scale
deletions are commonly found in dividing tissues [10], whereas
large-scale deletions are the predominant species of mtDNA
mutation in post-mitotic tissues [33,44]. In addition, it has been
shown that in mice with two different mitochondrial genotypes,
there is tissue specific accumulation of one genotype over another
[45]. Therefore a literature search was carried out and a dataset of
mtDNA point mutations in normal ageing tissues compiled.
Mutations were only included if they had been detected using the
same methodology and quality control analyses as the mutations
detected in the colonic epithelium, and were in normal, not
tumour tissues. A total of 24 mutations were included from
stomach epithelium [27], prostatic epithelium [46], bladder
urothelium [47], small intestinal epithelium [48], pancreas [49]
and liver [26,37]. All mutations were detected in COX deficient
cells. Full details of all mutations are in Table S4. The mutations
detected had a similar mutation spectrum as the colon mutations,
with 92% of the mutations being transitions, 4% transversions and
4% single base pair deletions. Due to the small size of the dataset,
it was not possible to do a detailed comparison of the location of
the mutations, but mutations were found in all gene types (protein
encoding, mt-rRNA and mt-tRNA genes). There were 8 non-
synonymous protein encoding mutations, all in COX encoding
genes, which had a mean MutPred score of 0.81160.03. This was
then compared to the MutPred score for COX-encoding gene
mutations in COX deficient cells of the colon. To exclude the
effects of multiple mtDNA mutations within a cell, mutations were
only included if they were either the only mutation in the cell, or
the only coding-region mutation in the cell. There was no
significant difference in the MutPred score between the mtDNA
mutations in the colonic crypts (0.74360.03, n= 10) and those in
the other tissues analysed (p = 0.07, Wilcoxon rank sum test).
These data provide evidence that occurrence and clonal expansion
of pathogenic protein encoding mutations with age is not restricted
to only the colonic epithelium, but is likely to be relevant to other
mitotic tissues.
Discussion
The aim of this study was to compare the selective constraints
on the occurrence and expansion of age-related mtDNA mutations
in the human colon with those in the general population and those
which cause primary mtDNA disease. Purifying selection in the
germline has been demonstrated in two studies using two different
mouse models. One group utilised a mouse with a homozygous
knock-in allele expressing a proof-reading- deficient mtDNA
polymerase c which, as a consequence, accumulates high levels of
random mtDNA point mutations [23]. This mouse was back-
crossed with mice with wild-type mtDNA polymerase and the
offspring showed rapid elimination from the germline of non-
synonymous protein encoding mutations. A complementary study
generated a mouse model of mtDNA disease with 2 mtDNA
mutations, one relatively mild mtDNA mutation and one severe
mtDNA mutation. Only the mild mutation was transmitted
through the germline to the next generation. [24]. The reduction
of mtDNA copy number at the mtDNA bottleneck followed by
huge expansion of a small number of mtDNA molecules allows
rapid fixation of new mtDNA mutations and the opportunity to
select against deleterious mutants by unknown mechanisms which
could operate at the DNA, organelle or cellular level (primordial
germ cell lineage) [50].
Our study has shown no evidence for the action of purifying
selection on age-related mtDNA mutations in a number of
different tissue types, which we observed are distributed randomly
throughout the mitochondrial genome. Further, frequency of age-
related mtDNA mutations in each gene is equal to the proportion
of the mitochondrial genome occupied by that gene suggesting
that there is no functional selection. There was a predominance of
transition mutations compared with transversions and insertions/
deletions, with 65% of those transitions being C:G to T:A
mutations. These mutation types are likely to be due to errors
during replication of mtDNA and/or spontaneous cytosine
deamination [51], the remaining transitions are likely to be due
to replication errors. There was only one C:G to A:T mutation in
the dataset, suggesting that there is little contribution of 8-oxo-
deoxyguanine mediated mutagenesis, thus casting doubt on the
importance of oxidative damage in ageing, at least in this tissue
type. The mutational spectrum here probably reflects the initial
mechanism of mutation occurrence rather than selection during
clonal expansion.
There were differences between the somatic age-related
mtDNA mutations and the mutations we observe in the general
population. The most prominent differences are the expansion of
non-synonymous protein encoding mutations, including frameshift
and termination mutations, in somatic cells compared with the
germline, and the higher pathogenicity scores of the age-related
mutations. These observations provide evidence that there is little
or no selection against pathogenic mutations in the soma, whereas
the germline is relatively protected from such mutations by the
mtDNA bottleneck [52]. Pathogenic mtDNA mutations in both
mt-tRNA genes and mt-mRNA genes which cause disease can
either be maternally- inherited or sporadic. Our predicted
pathogenicity analysis of the mutations in the protein encoding
genes shows that those which are sporadic, and therefore occur
post-bottleneck, are more pathogenic than those which are
inherited. The high prevalence of mt-tRNA mutations which
cause primary mtDNA disease suggests that they are passed
through the germline more easily than mt-mRNA variants,
perhaps because in the majority of cases they produce a less
severe phenotype [7,40]. The mouse study by Stewart et al., also
showed no evidence of purifying selection on mt-tRNA mutations
[23].
A number of the mtDNA mutations detected in the human
colon were also associated with loss of COX activity, and COX
deficiency is a common observation in patients with mtDNA
disease. This suggests that mitochondrial quality control systems
such as mitophagy have limited efficiency to remove dysfunctional
mitochondria to restore normal function. This is in contrast to a
study in which Parkin, an E3 ligase which selectively translocates
to depolarised mitochondria and activates their elimination by
autophagy, was continually overexpressed in a cybrid cell line
containing a mutation in MT-CO1 [53]. Parkin overexpression
resulted in selective degradation of dysfunctional mitochondria, an
increase in the proportion of wild-type mtDNA, and restoration of
COX activity. In our study we see accumulation of pathogenic
With six tests, the threshold for significance is 0.05/6 = 0.008, ** = p,0.0017, *** = p,0.00017. B: The distribution of pathogenicity scores including
synonymous mtDNA mutations which were assigned a pathogenicity score of 0, in ageing, population and disease. Results of Wilcoxon rank sum
analysis are shown. With three tests the threshold for significance is 0.05/3 = 0.017, ** = p,0.003, *** = p,0.0003. C: The distribution of pathogenicity
scores in sporadic and inherited disease-causing mtDNA mutations. Results of Wilcoxon rank sum test are shown,* p,0.05.
doi:10.1371/journal.pgen.1003082.g003
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mtDNA mutations in individual cells. The difference could either
be because mtDNA mutations which lower membrane potential to
the extent by which Parkin becomes activated are selected against
and are therefore not able to accumulate in individual somatic
cells, or that physiologically normal levels of Parkin do not have
the same effect as Parkin over expression.
These studies have shown that mutations in genes other than
MT-CO genes can result in COX deficiency. Disease-associated
mutations in mt-tRNA genes are commonly associated with COX
defects [54]and mutations in mt-rRNA genes could be causing a
translational defect to explain the COX deficiency. We have
previously shown that multiple respiratory chain complex
deficiency is a common occurrence in the human colon, with
approximately 50% of crypts exhibiting COX deficiency also
showing a loss of complex I and III subunits immunohistochem-
ically [38]. This multiple respiratory chain complex deficiency
could therefore be attributed to mutations in any of the mt-mRNA
genes, explaining why we observe COX deficiency associated with
mutations in non-MTCO genes. Multiple biochemical defects have
been observed in patients with mutations in structural subunits of
complex I [55] and complex III [56,57] highlighting the fact that
complexes of the respiratory chain do not simply exist as simple
entities but associate to form ‘supercomplexes’ [58,59]. Moreover,
it has recently been shown that if one component complex is
absent, supercomplexes are not formed [58] and that the
incorporation of a defective structural component, such as a
truncated form of COX1, can lead to the rapid degradation of
supercomplexes and downregulation of other mitochondrially-
encoded respiratory chain subunits [60]
From an evolutionary perspective, our data are consistent with
the predictions of the disposable soma theory of ageing [3]. By
comparing the somatic age-related mtDNA mutations which
clonally expand within individual cells of the colon with those
passed through the germline in populations we have shown
considerable evidence supporting the hypothesis that there is
selection against pathogenic mtDNA mutations in the human
germ-line but little evidence of any such selection in the somatic
tissues studied here.
As there are multiple copies of the mitochondrial genome in an
individual cell, any mutation occurring in one molecule will be
functionally recessive [61]. A functional defect becomes apparent
only when a mutation expands clonally to high levels in a cell
(typically .70%) [7]. Numerous studies in human tissues have
shown an age-dependent increase in the fraction of individual cells
which are respiratory-chain deficient [10,25,27–29,49] and that
the cause of respiratory chain deficiency is clonally expanded
somatic mtDNA mutations [10,27,62]. Since our data suggest that
there is no obvious imprint of selection on the spectrum of age-
related mtDNA mutations in the human colon, it remains of
interest to consider how such clonal expansion occurs. One
leading hypothesis, supported by computational models, is that
clonal expansion occurs simply through a process of random
genetic drift [63]. Unlike nuclear DNA, mitochondrial DNA is
replicated independently of the cell cycle and not all molecules are
always replicated (relaxed replication) [14]. The random genetic
drift hypothesis suggests that relaxed replication of mtDNA
coupled with random degradation of some mtDNA molecules
can lead to one mutant genotype becoming the dominant
genotype of the cell. A study using heteroplasmic mice containing
two different mtDNA genotypes measured the relative contribu-
tion of each genotype in individual colonic crypts over time. The
study showed that in individual crypts from 4 month old mice
there was a mixture of the two genotypes, however in the crypts of
the 15 month old mice two distinct crypt populations were
observed with one or other of the genotypes predominating. This
experimental data fits with a model of neutral drift [45]. In
humans, the random genetic drift model predicts that clonal
expansion takes decades to occur [63]. Experimental data from a
number of tissues has shown that respiratory chain deficient cells
are not detectable in humans before approximately age 35 years
[10,28], and in the human colon we have shown previously that
such defects are present in one third or more of colonocytes from
those aged 70+ [10]. This, coupled with the mutational spectrum
detected in the human colon is supportive of the ‘early mutation,
slow expansion’ theory of mitochondrial ageing [64].
In conclusion, these investigations have shown significant
differences in the spectrum and predicted pathogenicity of mtDNA
mutations in the somatic tissues studied here which are associated
with ageing, rare population variants which have passed through
the germ-line and those pathogenic mtDNA mutations associated
with disease. We found little evidence for purifying selection in the
somatic tissues investigated, whereas there is strong evidence for
purifying selection in the germ-line.
Materials and Methods
Generation of a dataset of age-associated somatic
mtDNA mutations
Colorectal mucosal samples were collected from the same
anatomical site (10 cm from the anal verge) from subjects (n = 9,
age range 71–78 years) undergoing colonoscopy for disturbed
bowel function in whom no evidence of bowel disease was
identified (BORICC 1 Study). Informed consent was given by all
participants in the study and ethical approval was obtained from
the Northumbria NHS Trust Local Research Ethics Committee
(project reference 04/Q0902/6/).
Single colonocytes were laser-microdissected into sterile 0.5 ml
PCR tubes using a Leica Laser Microdissection (AS-LMD)
System. Following centrifugation (70006g for 10 min), the cell
was lysed in 14 ml of cell lysis buffer (50 mM Tris-HCl pH 8.5,
1 mM EDTA, 0.5% Tween-20, 200 ng/ml proteinase K) at 55uC
for 2 hours and then 95uC for 10 minutes to denature the
proteinase K. The entire sequence of the mitochondrial genome
from microdissected colonocytes was determined using the single
cell lysate as the DNA template. Two rounds of PCR were carried
out as previously described [10]. PCR products were cycle
sequenced using ABI BigDye chemistries per standard manufac-
turer’s protocols and analysed on an ABI3100 genetic analyser
(Applied Biosystems). Sequences obtained were compared with the
rCRS [42] and the homogenate sequence for each patient
(phylogenetic quality control), using SeqScape software (Applied
Biosystems). Due to potential problems with low mtDNA copy
number PCR [65], all putative mutations were re-amplified from
the original DNA lysate and were sequenced in both the forward
and reverse directions. This strategy aimed to eliminate any errors
due to either amplification of nuclear pseudogenes or errors
introduced by the DNA polymerase during PCR amplification.
These mutations were added to an existing database of published
somatic mtDNA mutations detected in the ageing colon [9,10,38].
A full list of mutations can be found in Table S1.
Generation of a disease-associated mtDNA mutation data
set
Due to the inherent difficulty in assigning pathogenicity to
reported mtDNA disease-associated mutations we applied strict
criteria when assembling a database of such mutations for the
purpose of this study. Protein encoding mutations were included
only if they were assigned as ‘probably’ or ‘definitely pathogenic’
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using a validated scoring system designed in this laboratory [66].
Our database includes all such mutations previously assigned
pathogenicity scores by Wong in 2007 [67], as well as 4 more
recently published mutations which were shown to score in these
categories [68–71]. We also included tRNA mutations proven to
be pathogenic by a similar scoring system [72]. Only two rRNA
mutations have been confirmed on mitomap to be pathogenic and
therefore only these two were included in the analysis [73]. A full
list of mutations can be found in Table S2.
Rare population mtDNA variant dataset
All of the participants whose data were included in the ageing
mutation database were of European haplotype therefore the 100
European coding region sequences were chosen. The 100
European sequences were randomly selected reflecting the
European haplogroup distribution. The sequences were drawn
from the MitoKor database, the changes selected as the rare
population variants (Table S3) had been classified as ‘‘private’’ for
the purposes of the MitoKor database. In the context of the
‘‘Mitokor’’ database a private change was one that was seen in a
single individual only from a continental group i.e. for the
European sequences it was seen in only one from 433 individuals.
In the time since the generation of the MitoKor database there has
been a vast increase in the amount of available sequences but the
variants analysed remain a pool of rare variants on European
haplogroup backgrounds. In addition, all sequencing to yield data
for the Mitokor database was carried out with fourfold redundancy
which provides confidence that these are rare variants not
sequencing errors.
Pathogenicity scoring
The pathogenicity of non-synonymous mutations in the 13
protein encoding genes was predicted using the computational
software MutPred [41], which is based on the established SIFT
method [74,75]. The MutPred scores for all 24,206 possible amino
acid variations published by Pereira et al [43] were also included
in these analyses.
Supporting Information
Table S1 Somatic mitochondrial DNA point mutations detected
in ageing human colonic crypt cells.
(XLSX)
Table S2 Mitochondrial DNA point mutations which are
reported to cause human mitochondrial disease.
(XLSX)
Table S3 Rare population variants in 100 European coding
region mitochondrial DNA sequences.
(XLSX)
Table S4 Somatic mitochondrial DNA point mutations reported
in ageing human tissues.
(XLSX)
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